Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure

Inclusion Criteria: * Age ≥18 years and ability to understand the planned treatment. * Patients with Congestive Heart Failure * Left ventricular ejection fraction ≤40% by echocardiogram, per ECHO completed 30 days prior to treatment * Symptomatic heart failure NYHA class III or IV * Able to comply with all study-related visits * Able to tolerate study procedures, including bone marrow aspiration, SPECT, * Able to give informed Consent * Negative for HcG with a serum pregnancy test * Patients with controlled diabetes mellitus (HbA1c \< 9.0%) * Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, * Life expectancy of 6 months or more in the opinion of the investigator * Patients requiring high dose corticosteroid therapy (more than 7.5 mg/day) with 1 month before the aspiration or 6 months after the infusion. * Serum bilirubin, ALT, AST ≤2.5 time the upper level of normal. * Controlled blood pressure (systolic blood pressure ≤140 and a diastolic blood pressure of ≤90 mmHG) and established anti-hypertensive therapy as necessary prior to entry into the study * Patient has received stable, standard medical therapy for at least one month with no new medications to treat the disease introduced in the last 3 months. * Pre-existing condition (e.g. thromboembolic risk, diabetes, hypercholesterolemia are adequately controlled in the opinion of the investigator) * Fertile patients (male and female) must agree to use an appropriate form of contraception while participating in the study. Exclusion Criteria: * Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study. * History of prior radiation exposure for oncological treatment. * History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation. * History of abnormal bleeding or clotting. * History of Liver Cirrhosis. * End stage renal disease (Creatinine ≤ 3.0 mg / dl) and/or dialysis * Acute Myocardial Infarction \< 1 week from treatment date. * Active clinical infection being treated by antibiotics within one week of enrollment * Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent. * Unable to have 250cc bone marrow harvested. * History of life-threatening arrhythmias, except if an automated implantable cardioverter defibrillator (AICD) is implanted * Life expectancy \<6 months due to concomitant illnesses * Known cancer and undergoing treatment; chemotherapy and/or radiotherapy * Patients receiving treatment with hematopoietic growth factors (e.g., EPO, G-CSF) * Patients who can not stop anticoagulation therapy (warfarin) 72hrs prior to bone marrow aspiration and infusion * Patients who can not stop anti-platelet therapy (clopidogrel) 7 days prior to bone marrow aspiration and infusion * History of alcohol consumption exceeding the equivalent of 2 drinks/daily (1 drink = 5oz wine, 12oz of beer, or 1.5oz hard liquor) or illicit drug use within 6 months of screening. * Patient who will require continuous high dose corticosteroid therapy (more than 7.5mg/day) within 1 month before aspiration or 6 months after injection procedure. * Body Mass Index (BMI) of 40 kg/m2 or greater * Patient receiving experimental medication or participating in another clinical study within 30 days of signing the informed consent * In the opinion of the investigator or the sponsor, the patient is unsuitable for cellular therapy * Known allergy or sensitivity to contrast agents used in imaging procedures.